Perspective Therapeutics, Inc. - 8-K Filing

Perspective Therapeutics reports promising interim Phase 1/2a monotherapy data for VMT01 in advanced melanoma patients at SITC 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CATX

Read the full article at SEC EDGAR

More Regulatory news